Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 145

1.

Prolonged survival in the absence of disease-recurrence in advanced-stage follicular lymphoma following chemo-immunotherapy: 13-year update of the prospective, multicenter randomized GITMO-IIL trial.

Bruna R, Benedetti F, Boccomini C, Patti C, Barbui AM, Pulsoni A, Musso M, Liberati AM, Gini G, Castellino C, Rossini F, Ciceri F, Rota-Scalabrini D, Stelitano C, Di Raimondo F, Tucci A, Devizzi L, Zoli V, Zallio F, Narni F, Dondi A, Parvis G, Semenzato G, Lanza F, Perrone T, Angrilli F, Billio A, Gueli A, Mantoan B, Rambaldi A, Gianni AM, Corradini P, Passera R, Ladetto M, Tarella C.

Haematologica. 2019 Nov;104(11):2241-2248. doi: 10.3324/haematol.2018.209932. Epub 2019 Apr 11.

2.

Preliminary results of a counselling programme for fertility preservation in female cancer patients: The experience of the GEMME DORMIENTI network.

Ciccarone M, Hohaus S, Pulsoni A, Cavaceppi P, Franzò S, Fabbri R, Cudillo L, Battistini R, Di Rocco A, Annibali O, Cox MC, Provenzano I, Abruzzese E, Renzi D, Tesei C, Anticoli Borza P, Cuccaro A, Andriani A, D'Elia GM, Facchiano A, Marchetti P, Cantonetti M.

Eur J Cancer Care (Engl). 2019 Sep 30:e13174. doi: 10.1111/ecc.13174. [Epub ahead of print]

PMID:
31571303
3.

Response to Interferon-Free Direct Antivirals (DAAS) Treatment in Hcv-Related Subcutaneous Marginal Zone B-Cell Lymphoma with Lipoma-Like Presentation: Report of Two Cases.

De Luca ML, Lombardi L, Tartaglia G, Fazio F, Di Prima A, Serrao A, Canichella M, Pulsoni A.

Mediterr J Hematol Infect Dis. 2019 Sep 1;11(1):e2019053. doi: 10.4084/MJHID.2019.053. eCollection 2019.

4.

Minimal residual disease monitoring in early stage follicular lymphoma can predict prognosis and drive treatment with rituximab after radiotherapy.

Pulsoni A, Della Starza I, Cappelli LV, Tosti ME, Annechini G, Cavalli M, De Novi LA, D'Elia GM, Grapulin L, Guarini A, Del Giudice I, Foà R.

Br J Haematol. 2019 Aug 5. doi: 10.1111/bjh.16125. [Epub ahead of print]

PMID:
31385309
5.

Thrombopoietin receptor agonists to control immune thrombocytopenia in patients with active lymphoma.

Ferretti A, Baldacci E, Miulli E, Canichella M, Di Rocco A, Pulsoni A, Martelli M, Serrao A, Chistolini A, Gabriella Mazzucconi M, Foà R, Santoro C.

Br J Haematol. 2019 Sep;186(6):e217-e219. doi: 10.1111/bjh.16114. Epub 2019 Jul 31. No abstract available.

PMID:
31364154
6.

Bleomycin, vinblastine and dacarbazine combined with nonpegylated liposomal doxorubicin (MBVD) in elderly (≥70 years) or cardiopathic patients with Hodgkin lymphoma: a phase-II study from Fondazione Italiana Linfomi (FIL).

Salvi F, Luminari S, Tucci A, Massidda S, Liberati AM, Stelitano C, Zanni M, Re A, Centurioni R, Freilone R, Musuraca G, Nassi L, Patti C, Arcari A, Tani M, Pulsoni A, Pavone V, Volpetti S, Peli A, Evangelista A, Spina M, Ladetto M, Merli F.

Leuk Lymphoma. 2019 Dec;60(12):2890-2898. doi: 10.1080/10428194.2019.1608529. Epub 2019 Jul 8.

PMID:
31282794
7.

Long-lasting persistence of large B-cell clones in hepatitis C virus-cured patients with complete response of mixed cryoglobulinaemia vasculitis.

Visentini M, Del Padre M, Colantuono S, Yang B, Minafò YA, Antonini S, Carnovale M, De Santis A, Pulsoni A, De Sanctis GM, Gragnani L, Zignego AL, Fiorilli M, Casato M.

Liver Int. 2019 Apr;39(4):628-632. doi: 10.1111/liv.14053. Epub 2019 Feb 15.

PMID:
30690862
8.

Long-term response to daratumumab in a patient with advanced immunoglobulin light-chain (AL) amyloidosis with organ damage.

Canichella M, Serrao A, Annechini G, D'Elia GM, De Luca ML, Pulsoni A.

Ann Hematol. 2019 Apr;98(4):1047-1048. doi: 10.1007/s00277-018-3566-4. Epub 2018 Nov 28. No abstract available.

PMID:
30488327
9.

Nivolumab as a safe and effective treatment in an HIV patient with refractory Hodgkin lymphoma.

Serrao A, Canichella M, De Luca ML, Tartaglia G, Annechini G, D'Elia GM, Pulsoni A.

Ann Hematol. 2019 Jun;98(6):1505-1506. doi: 10.1007/s00277-018-3541-0. Epub 2018 Nov 9. No abstract available.

PMID:
30413900
10.

Radiation therapy in indolent primary cutaneous B cell lymphoma: a single institute experience.

De Felice F, Grapulin L, Pieroni A, Salerno F, D'Elia GM, Pulsoni A, Musio D, Tombolini V.

Ann Hematol. 2018 Dec;97(12):2411-2416. doi: 10.1007/s00277-018-3471-x. Epub 2018 Aug 10.

PMID:
30094511
11.

Current and future therapeutic approaches for the treatment of follicular lymphoma.

Pulsoni A, Cappelli LV, Ballotta L, Canichella M, Serrao A, Annechini G, D'Elia GM, Foà R.

Expert Rev Anticancer Ther. 2018 Sep;18(9):931-941. doi: 10.1080/14737140.2018.1493926. Epub 2018 Jul 16. Review.

PMID:
29972084
12.

Radiotherapy in indolent primary cutaneous B-cell lymphoma.

De Felice F, Grapulin L, Pieroni A, Salerno F, D'Elia GM, Pulsoni A, Musio D, Tombolini V.

Hematol Oncol. 2018 Jun 3. doi: 10.1002/hon.2518. [Epub ahead of print] No abstract available.

PMID:
29862552
13.

Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma.

Pellegrini C, Broccoli A, Pulsoni A, Rigacci L, Patti C, Gini G, Mannina D, Tani M, Rusconi C, Romano A, Vanazzi A, Botto B, Santoro A, Hoaus S, Rigolin GM, Musto P, Mazza P, Molica S, Corradini P, Fama A, Gaudio F, Merli M, Ronconi F, Gritti G, Vallisa D, Tosi P, Liberati AM, Pinto A, Pavone V, Gherlinzoni F, Bianchi MP, Volpetti S, Trentin L, Goldaniga MC, Bonfichi M, De Renzo A, Schiavotto C, Spina M, Carella AM, Stefoni V, Argnani L, Zinzani PL.

Oncotarget. 2017 May 23;8(53):91703-91710. doi: 10.18632/oncotarget.18114. eCollection 2017 Oct 31.

14.

Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma.

Luminari S, Ferrari A, Manni M, Dondi A, Chiarenza A, Merli F, Rusconi C, Tarantino V, Tucci A, Vitolo U, Kovalchuk S, Angelucci E, Pulsoni A, Arcaini L, Angrilli F, Gaidano G, Stelitano C, Bertoldero G, Cascavilla N, Salvi F, Ferreri AJM, Vallisa D, Marcheselli L, Federico M.

J Clin Oncol. 2018 Mar 1;36(7):689-696. doi: 10.1200/JCO.2017.74.1652. Epub 2017 Nov 2.

PMID:
29095677
15.

Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: a systematic review and meta-analysis of randomized clinical trials.

Eichenauer DA, Becker I, Monsef I, Chadwick N, de Sanctis V, Federico M, Fortpied C, Gianni AM, Henry-Amar M, Hoskin P, Johnson P, Luminari S, Bellei M, Pulsoni A, Sydes MR, Valagussa P, Viviani S, Engert A, Franklin J.

Haematologica. 2017 Oct;102(10):1748-1757. doi: 10.3324/haematol.2017.167478. Epub 2017 Sep 14. Review.

16.

Comparative analysis between RQ-PCR and digital droplet PCR of BCL2/IGH gene rearrangement in the peripheral blood and bone marrow of early stage follicular lymphoma.

Cavalli M, De Novi LA, Della Starza I, Cappelli LV, Nunes V, Pulsoni A, Del Giudice I, Guarini A, Foà R.

Br J Haematol. 2017 May;177(4):588-596. doi: 10.1111/bjh.14616. Epub 2017 Apr 17.

PMID:
28419517
17.

Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia.

Gragnani L, Visentini M, Fognani E, Urraro T, De Santis A, Petraccia L, Perez M, Ceccotti G, Colantuono S, Mitrevski M, Stasi C, Del Padre M, Monti M, Gianni E, Pulsoni A, Fiorilli M, Casato M, Zignego AL.

Hepatology. 2016 Nov;64(5):1473-1482. doi: 10.1002/hep.28753. Epub 2016 Aug 29.

PMID:
27483451
18.

Reappraising the timing of transplant for indolent non-Hodgkin lymphomas.

Capria S, Barberi W, Perrone S, Ferretti A, Salaroli A, Annechini G, D'Elia GM, Foà R, Pulsoni A.

Expert Rev Hematol. 2016 Oct;9(10):951-64. doi: 10.1080/17474086.2016.1226128. Epub 2016 Aug 31. Review.

PMID:
27539362
19.

Bendamustine in Combination With Gemcitabine and Vinorelbine Is an Effective Regimen As Induction Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma: Final Results of a Multicenter Phase II Study.

Santoro A, Mazza R, Pulsoni A, Re A, Bonfichi M, Zilioli VR, Salvi F, Merli F, Anastasia A, Luminari S, Annechini G, Gotti M, Peli A, Liberati AM, Di Renzo N, Castagna L, Giordano L, Carlo-Stella C.

J Clin Oncol. 2016 Sep 20;34(27):3293-9. doi: 10.1200/JCO.2016.66.4466. Epub 2016 Jul 5.

20.

Blastic plasmacytoid dendritic cell neoplasm: diagnostic criteria and therapeutical approaches.

Pagano L, Valentini CG, Grammatico S, Pulsoni A.

Br J Haematol. 2016 Jul;174(2):188-202. doi: 10.1111/bjh.14146. Epub 2016 Jun 5. Review.

PMID:
27264021
21.

Splenic marginal zone lymphoma: Prognostic factors, role of watch and wait policy, and other therapeutic approaches in the rituximab era.

Perrone S, D'Elia GM, Annechini G, Ferretti A, Tosti ME, Foà R, Pulsoni A.

Leuk Res. 2016 May;44:53-60. doi: 10.1016/j.leukres.2016.03.005. Epub 2016 Mar 22.

PMID:
27030961
22.

90-yttrium-ibritumomab tiuxetan consolidation of fludarabine, mitoxantrone, rituximab in intermediate/high-risk follicular lymphoma: updated long-term results after a median follow-up of 7 years.

Casadei B, Pellegrini C, Pulsoni A, Annechini G, De Renzo A, Stefoni V, Broccoli A, Gandolfi L, Quirini F, Tonialini L, Morigi A, Argnani L, Zinzani PL.

Cancer Med. 2016 Jun;5(6):1093-7. doi: 10.1002/cam4.684. Epub 2016 Mar 14.

23.

Interim Positron Emission Tomography Response-Adapted Therapy in Advanced-Stage Hodgkin Lymphoma: Final Results of the Phase II Part of the HD0801 Study.

Zinzani PL, Broccoli A, Gioia DM, Castagnoli A, Ciccone G, Evangelista A, Santoro A, Ricardi U, Bonfichi M, Brusamolino E, Rossi G, Anastasia A, Zaja F, Vitolo U, Pavone V, Pulsoni A, Rigacci L, Gaidano G, Stelitano C, Salvi F, Rusconi C, Tani M, Freilone R, Pregno P, Borsatti E, Sacchetti GM, Argnani L, Levis A.

J Clin Oncol. 2016 Apr 20;34(12):1376-85. doi: 10.1200/JCO.2015.63.0699. Epub 2016 Feb 16.

24.

Infectious Aetiology of Marginal Zone Lymphoma and Role of Anti-Infective Therapy.

Perrone S, D'Elia GM, Annechini G, Pulsoni A.

Mediterr J Hematol Infect Dis. 2016 Jan 1;8(1):e2016006. doi: 10.4084/MJHID.2016.006. eCollection 2016. Review.

25.

Spermatogenesis in Hodgkin's lymphoma patients: a retrospective study of semen quality before and after different chemotherapy regimens.

Paoli D, Rizzo F, Fiore G, Pallotti F, Pulsoni A, Annechini G, Lombardo F, Lenzi A, Gandini L.

Hum Reprod. 2016 Feb;31(2):263-72. doi: 10.1093/humrep/dev310. Epub 2015 Dec 23.

PMID:
26705149
26.

Risk of secondary hypogammaglobulinaemia after Rituximab and Fludarabine in indolent non-Hodgkin lymphomas: A retrospective cohort study.

De Angelis F, Tosti ME, Capria S, Russo E, D'Elia GM, Annechini G, Stefanizzi C, Foà R, Pulsoni A.

Leuk Res. 2015 Dec;39(12):1382-8. doi: 10.1016/j.leukres.2015.10.013. Epub 2015 Nov 4.

PMID:
26547259
27.

Brentuximab Vedotin in Transplant-Naïve Relapsed/Refractory Hodgkin Lymphoma: Experience in 30 Patients.

Zinzani PL, Pellegrini C, Cantonetti M, Re A, Pinto A, Pavone V, Rigacci L, Celli M, Broccoli A, Argnani L, Pulsoni A.

Oncologist. 2015 Dec;20(12):1413-6. doi: 10.1634/theoncologist.2015-0227. Epub 2015 Oct 23.

28.

A phase II study of bendamustine in combination with rituximab as initial treatment for patients with indolent non-follicular non-Hodgkin lymphoma.

Luminari S, Goldaniga M, Cesaretti M, Orsucci L, Tucci A, Pulsoni A, Salvi F, Arcaini L, Carella AM, Tedeschi A, Pinto A, Stelitano C, Baldini L.

Leuk Lymphoma. 2016;57(4):880-7. doi: 10.3109/10428194.2015.1091934. Epub 2016 Feb 8.

PMID:
26379040
29.

Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia.

Tiacci E, Park JH, De Carolis L, Chung SS, Broccoli A, Scott S, Zaja F, Devlin S, Pulsoni A, Chung YR, Cimminiello M, Kim E, Rossi D, Stone RM, Motta G, Saven A, Varettoni M, Altman JK, Anastasia A, Grever MR, Ambrosetti A, Rai KR, Fraticelli V, Lacouture ME, Carella AM, Levine RL, Leoni P, Rambaldi A, Falzetti F, Ascani S, Capponi M, Martelli MP, Park CY, Pileri SA, Rosen N, Foà R, Berger MF, Zinzani PL, Abdel-Wahab O, Falini B, Tallman MS.

N Engl J Med. 2015 Oct 29;373(18):1733-47. doi: 10.1056/NEJMoa1506583. Epub 2015 Sep 9.

30.

Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone as first-line treatment for splenic marginal zone lymphoma: a Fondazione Italiana Linfomi phase II study.

Iannitto E, Luminari S, Tripodo C, Mancuso S, Cesaretti M, Marcheselli L, Merli F, Stelitano C, Carella AM, Fragasso A, Montechiarello E, Ricciuti G, Pulsoni A, Paulli M, Franco V, Federico M.

Leuk Lymphoma. 2015;56(12):3281-7. doi: 10.3109/10428194.2015.1029925. Epub 2015 Jul 18.

PMID:
25791121
31.

The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study.

Rossi D, Bruscaggin A, La Cava P, Galimberti S, Ciabatti E, Luminari S, Rigacci L, Tucci A, Pulsoni A, Bertoldero G, Vallisa D, Rusconi C, Spina M, Arcaini L, Angrilli F, Stelitano C, Merli F, Gaidano G, Federico M, Palumbo GA.

Haematologica. 2015 Apr;100(4):517-24. doi: 10.3324/haematol.2014.108183. Epub 2015 Jan 16.

32.

The use of anthracycline at first-line compared to alkylating agents or nucleoside analogs improves the outcome of salvage treatments after relapse in follicular lymphoma The REFOLL study by the Fondazione Italiana Linfomi.

Rossi G, Marcheselli L, Dondi A, Bottelli C, Tucci A, Luminari S, Arcaini L, Merli M, Pulsoni A, Boccomini C, Puccini B, Micheletti M, Martinelli G, Rossi A, Zilioli VR, Bozzoli V, Balzarotti M, Bolis S, Cabras MG, Federico M.

Am J Hematol. 2015 Jan;90(1):56-61. doi: 10.1002/ajh.23872. Epub 2014 Nov 19.

33.

Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: the FIL FOLL05 trial.

Galimberti S, Luminari S, Ciabatti E, Grassi S, Guerrini F, Dondi A, Marcheselli L, Ladetto M, Piccaluga PP, Gazzola A, Mannu C, Monitillo L, Mantoan B, Del Giudice I, Della Starza I, Cavalli M, Arcaini L, Tucci A, Palumbo GA, Rigacci L, Pulsoni A, Vitolo U, Boccomini C, Vallisa D, Bertoldero G, Gaidano G, Musto P, Petrini M, Federico M.

Clin Cancer Res. 2014 Dec 15;20(24):6398-405. doi: 10.1158/1078-0432.CCR-14-0407. Epub 2014 Oct 14.

34.

microRNA levels in paraffin-embedded indolent B-cell non-Hodgkin lymphoma tissues from patients chronically infected with hepatitis B or C virus.

Bruni R, Marcantonio C, Pulsoni A, Tataseo P, De Angelis F, Spada E, Marcucci F, Panfilio S, Bianco P, Riminucci M, Villano U, Tosti M, Ciccaglione A, Mele A.

BMC Infect Dis. 2014;14 Suppl 5:S6. doi: 10.1186/1471-2334-14-S5-S6. Epub 2014 Sep 5.

35.

Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi.

Arcaini L, Vallisa D, Rattotti S, Ferretti VV, Ferreri AJ, Bernuzzi P, Merli M, Varettoni M, Chiappella A, Ambrosetti A, Tucci A, Rusconi C, Visco C, Spina M, Cabras G, Luminari S, Tucci M, Musto P, Ladetto M, Merli F, Stelitano C, d'Arco A, Rigacci L, Levis A, Rossi D, Spedini P, Mancuso S, Marino D, Bruno R, Baldini L, Pulsoni A.

Ann Oncol. 2014 Jul;25(7):1404-10. doi: 10.1093/annonc/mdu166. Epub 2014 May 5.

PMID:
24799461
36.

The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale.

Gallamini A, Barrington SF, Biggi A, Chauvie S, Kostakoglu L, Gregianin M, Meignan M, Mikhaeel GN, Loft A, Zaucha JM, Seymour JF, Hofman MS, Rigacci L, Pulsoni A, Coleman M, Dann EJ, Trentin L, Casasnovas O, Rusconi C, Brice P, Bolis S, Viviani S, Salvi F, Luminari S, Hutchings M.

Haematologica. 2014 Jun;99(6):1107-13. doi: 10.3324/haematol.2013.103218. Epub 2014 Mar 21.

37.

Bendamustine for Hodgkin lymphoma patients failing autologous or autologous and allogeneic stem cell transplantation: a retrospective study of the Fondazione Italiana Linfomi.

Anastasia A, Carlo-Stella C, Corradini P, Salvi F, Rusconi C, Pulsoni A, Hohaus S, Pregno P, Viviani S, Brusamolino E, Luminari S, Giordano L, Santoro A.

Br J Haematol. 2014 Jul;166(1):140-2. doi: 10.1111/bjh.12821. Epub 2014 Mar 7. No abstract available.

PMID:
24606548
38.

Regression of a case of Multiple Myeloma with antiviral treatment in a patient with chronic HCV infection.

Panfilio S, D'Urso P, Annechini G, D'Elia GM, De Angelis F, Stefanizzi C, Pulsoni A.

Leuk Res Rep. 2013 May 17;2(1):39-40. doi: 10.1016/j.lrr.2013.01.002. eCollection 2013.

39.

Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program.

Ladetto M, Lobetti-Bodoni C, Mantoan B, Ceccarelli M, Boccomini C, Genuardi E, Chiappella A, Baldini L, Rossi G, Pulsoni A, Di Raimondo F, Rigacci L, Pinto A, Galimberti S, Bari A, Rota-Scalabrini D, Ferrari A, Zaja F, Gallamini A, Specchia G, Musto P, Rossi FG, Gamba E, Evangelista A, Vitolo U; Fondazione Italiana Linfomi.

Blood. 2013 Nov 28;122(23):3759-66. doi: 10.1182/blood-2013-06-507319. Epub 2013 Oct 1.

40.

Identification of prognostic factors predicting outcome in Hodgkin's lymphoma patients relapsing after autologous stem cell transplantation.

Martínez C, Canals C, Sarina B, Alessandrino EP, Karakasis D, Pulsoni A, Sica S, Trneny M, Snowden JA, Kanfer E, Milpied N, Bosi A, Guidi S, de Souza CA, Willemze R, Arranz R, Jebavy L, Hellmann A, Sibon D, Oneto R, Luan JJ, Dreger P, Castagna L, Sureda A; Lymphoma Working Party of the European Group for Blood and Marrow Transplantation (EBMT) and the Gruppo Italiano Trapianto di Midollo Osseo (GITMO).

Ann Oncol. 2013 Sep;24(9):2430-4. doi: 10.1093/annonc/mdt206. Epub 2013 May 26.

PMID:
23712545
41.

R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi.

Federico M, Luminari S, Dondi A, Tucci A, Vitolo U, Rigacci L, Di Raimondo F, Carella AM, Pulsoni A, Merli F, Arcaini L, Angrilli F, Stelitano C, Gaidano G, Dell'olio M, Marcheselli L, Franco V, Galimberti S, Sacchi S, Brugiatelli M.

J Clin Oncol. 2013 Apr 20;31(12):1506-13. doi: 10.1200/JCO.2012.45.0866. Epub 2013 Mar 25. Erratum in: J Clin Oncol. 2014 Apr 1;32(10):1095. Dosage error in article text.

PMID:
23530110
42.

Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study.

Pagano L, Valentini CG, Pulsoni A, Fisogni S, Carluccio P, Mannelli F, Lunghi M, Pica G, Onida F, Cattaneo C, Piccaluga PP, Di Bona E, Todisco E, Musto P, Spadea A, D'Arco A, Pileri S, Leone G, Amadori S, Facchetti F; GIMEMA-ALWP (Gruppo Italiano Malattie EMatologiche dell'Adulto, Acute Leukemia Working Party).

Haematologica. 2013 Feb;98(2):239-46. doi: 10.3324/haematol.2012.072645. Epub 2012 Oct 12.

43.

The association of hepatitis B virus infection with B-cell non-Hodgkin lymphoma - a review.

Marcucci F, Spada E, Mele A, Caserta CA, Pulsoni A.

Am J Blood Res. 2012;2(1):18-28. Epub 2012 Jan 1.

44.

Impact of different treatment approaches on pregnancy outcomes in 99 women treated for Hodgkin lymphoma.

De Sanctis V, Filippone FR, Alfò M, Muni R, Cavalieri E, Pulsoni A, Annechini G, Valeriani M, Osti MF, Minniti G, Enrici RM.

Int J Radiat Oncol Biol Phys. 2012 Nov 1;84(3):755-61. doi: 10.1016/j.ijrobp.2011.12.066. Epub 2012 Mar 11.

PMID:
22414282
45.

Long-term efficacy and toxicity results of the FLUMIZ trial (fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in untreated follicular lymphoma).

Zinzani PL, Derenzini E, Pellegrini C, Rigacci L, Fabbri A, Gandolfi L, Argnani L, Casadei B, Pulsoni A, Gobbi M, Perotti A, Zaccaria A, Voso MT, Cabras MG, De Renzo A.

Ann Oncol. 2012 Mar;23(3):805-7. doi: 10.1093/annonc/mdr633. Epub 2012 Jan 27. No abstract available.

PMID:
22287683
46.

Fludarabine, cyclophosphamide, and rituximab in patients with advanced, untreated, indolent B-cell nonfollicular lymphomas: phase 2 study of the Italian Lymphoma Foundation.

Ferrario A, Pulsoni A, Olivero B, Rossi G, Vitolo U, Tedeschi A, Merli F, Rigacci L, Stelitano C, Goldaniga M, Mannina D, Musto P, Rossi F, Gamba E, Baldini L.

Cancer. 2012 Aug 15;118(16):3954-61. doi: 10.1002/cncr.26708. Epub 2011 Dec 16.

47.

Behind the scenes of non-nodal MCL: downmodulation of genes involved in actin cytoskeleton organization, cell projection, cell adhesion, tumour invasion, TP53 pathway and mutated status of immunoglobulin heavy chain genes.

Del Giudice I, Messina M, Chiaretti S, Santangelo S, Tavolaro S, De Propris MS, Nanni M, Pescarmona E, Mancini F, Pulsoni A, Martelli M, Di Rocco A, Finolezzi E, Paoloni F, Mauro FR, Cuneo A, Guarini A, Foà R.

Br J Haematol. 2012 Mar;156(5):601-11. doi: 10.1111/j.1365-2141.2011.08962.x. Epub 2011 Dec 8.

PMID:
22150124
48.

Remission of acquired von Willebrand syndrome after successful treatment of gastric MALT lymphoma.

Biondo F, Matturro A, Santoro C, Leporace A, D'Elia G, Baldacci E, Pignoloni P, Pulsoni A, Foà R, Mazzucconi M.

Haemophilia. 2012 Jan;18(1):e34-5. doi: 10.1111/j.1365-2516.2011.02681.x. Epub 2011 Nov 8. No abstract available.

PMID:
22059776
49.

Simple genetic diagnosis of hairy cell leukemia by sensitive detection of the BRAF-V600E mutation.

Tiacci E, Schiavoni G, Forconi F, Santi A, Trentin L, Ambrosetti A, Cecchini D, Sozzi E, Francia di Celle P, Di Bello C, Pulsoni A, Foà R, Inghirami G, Falini B.

Blood. 2012 Jan 5;119(1):192-5. doi: 10.1182/blood-2011-08-371179. Epub 2011 Oct 25. Erratum in: Blood. 2013 Aug 29;122(9):1685.

PMID:
22028477
50.

Primary uterine localization of malt lymphoma: a case report and literature review.

De Angelis F, Annechini G, Agostinelli C, D'Elia GM, Panfilio S, Pulsoni A.

Leuk Res. 2011 Nov;35(11):e185-7. doi: 10.1016/j.leukres.2011.07.003. Epub 2011 Jul 28. Review. No abstract available.

PMID:
21802137

Supplemental Content

Loading ...
Support Center